Clinical trial Recruiting at 1 site Interventional Ages 13 to 30

Investigating tibial tubercle osteotomy's role in knee ligament reconstruction

Official title: A Randomized Clinical Pilot Trial Comparing Isolated Medial Patellofemoral Ligament Reconstruction to Medial Patellofemoral Ligament Reconstruction Combined with Tibial Tubercle Osteotomy: SHould You TransFer the Tubercle (SHYFT)?

Run by Banff Sport Medicine Foundation · NCT05759039 · Data updated 2026-11-12

This study is testing if adding a specific knee surgery called tibial tubercle osteotomy to a ligament reconstruction can help people with repeated knee dislocations feel better.

More Patellofemoral Dislocation trials

Quick facts

Study typeInterventional
Ages13 Years to 30 Years
SexAll
Enrollment32 (estimated)
SponsorBanff Sport Medicine Foundation
Academic / other
Locations1 site (Canmore, Alberta)
StatusRecruiting
StartedSeptember 1, 2023
Main results expectedDecember 31, 2025
Study endsSeptember 1, 2026
Registry record updatedFebruary 4, 2025
Trial IDNCT05759039 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 13-30 with symptomatic recurrent lateral patellofemoral instability and a TT-TG distance of 15mm or greater.

Probably not a fit

Patients with significant osteoarthritis, high-grade trochlear dysplasia, or those unable to complete outcome questionnaires may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the impact of tibial tubercle osteotomy (TTO) on the outcomes of medial patellofemoral ligament reconstruction (MPFL-R) in patients experiencing recurrent lateral patellofemoral instability. The study will randomly assign participants to receive either an isolated MPFL-R or an MPFL-R combined with TTO, focusing on patients with an increased tibial tubercle-trochlear groove (TT-TG) distance. The trial will assess feasibility in terms of patient recruitment, adherence to protocols, and follow-up completion rates over a minimum of 12 months post-surgery.

Why it matters

Potential benefit: If successful, this study could improve surgical outcomes and quality of life for patients with recurrent knee instability.

How similar studies have gone: While the approach of combining TTO with MPFL-R is being explored, the specific correlation of TT-TG distance with patient outcomes remains under-researched, indicating a novel aspect to this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 13-30 years
* Symptomatic recurrent lateral patellofemoral instability
* TT-TG ≥15mm measured on MRI or ≥18mm on CT scan
* Closed physes (confirmed on knee x-rays)

Exclusion Criteria:

* Caton-Deschamps ratio ≥ 1.4 on lateral radiographs
* Femoral anteversion ≥ 25 degrees on diagnostic imaging rotational profile
* Tibial external rotation ≥ 45 degrees on diagnostic imaging rotational profile
* High-grade trochlear dysplasia requiring trochleoplasty
* Significant osteoarthritis on skyline plain imaging (Kellgren Lawrence grade ≥ 2)
* A chondral lesion of the patellofemoral joint that is undergoing a cartilage restoration procedure.
* Unable to complete computer-based outcome questionnaires
* Pregnant (at time of surgery)

Where it's running

  • Banff Sport Medicine
    Canmore, Alberta, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.